… state of MEK and ERK inhibitors in pre-clinical models and in human clinical trials for … MEK
inhibitor to date [75], single agent MEK inhibitors have only marginal activity in KRAS mutant …

… wild-type KRAS-dependent fitness of human and murine KRAS mutant LUAD … MEK inhibition.
These effects are abrogated when wild-type KRAS is replaced by KRAS D154Q , a mutant …

… /MEK inhibitors in the treatment of this disease. We describe the recent development of
the selective MEK inhibitor … with AKT inhibitor MK-2206 in KRAS mutant cancers, Citation101 …

… V600E/KRAS p.G12V double-positive clone rather than a therapy-induced KRAS mutation.
Because the patient received both BRAF and MEK inhibition, the double mutant clone may …

… hope of drugging KRAS. In this review, the latest research progress on KRAS, the characteristics
of KRAS mutations, the relationship between the KRAS mutations and tumour immunity, …

… Consequently, we hypothesized that the combination of a CDK4/6 inhibitor and a MEK
inhibitor would have synergistic antitumor activity in vitro and in vivo in KRAS mutant CRC. …

… inhibitor sensitivity of KRAS-mutant lung cancer cells To evaluate the global relevance of
PP2A activity for kinase inhibitor responses in human KRAS-mutant … (22) in KRAS-mutant A549 …

… Herein, we report that MEK inhibition leads to distinct activation of RTKs in KRAS-mutant lung
… In epithelial-like KRAS-mutant cancer cells, MEK inhibition upregulates ERBB3, which in …

… of KRAS, blocking this pathway with MEK inhibitors is … of MAPK signal following MEK inhibition
by multiple feedback … signaling following MEK inhibition in KRAS mutant lung cancer. In …

… cell lines, by measuring the reduction of phospho-MEK adaptive induction after … MEK
inhibitors led to enhanced antiproliferative activity and MAPK pathway suppression in KRAS-mutant …